Hyderabad, Jan. 6 -- Dr. Reddy's Laboratories Ltd on Tuesday announced the launch of Hevaxin(R), a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India, marking a significant milestone in preventive healthcare.
Hevaxin(R) is currently the only vaccine approved by the Drug Controller General of India (DCGI) for active immunisation against Hepatitis E in adults aged 18 to 65 years, the Hyderabad based Pharma giant said in a release here.
Clinical studies have demonstrated that the vaccine provides effective protection, supports long-lasting immunity, and has shown a favourable safety and tolerability profile.
According to the World Health Organization (WHO), Hepatitis E affects nearly 20 million people...